Drug Hunter
MAY 21, 2023
This “journal club” article highlights five recent articles of general interest to drug discovery scientists, including reviews on therapeutic areas of interest, principles and areas of medicinal chemistry and pharmacology, and a synthetic transformation worth keeping in mind. 1. A “Magic Chloro” Med. Chem. Review D. Chiodi and Y. Ishihara (Vividion) J.
Drug Discovery World
MAY 26, 2023
News round-up for 22-26 May by DDW Digital Content Editor Diana Spencer. The theme of our news review this week is money. Although Clarivate has reported a recent drop in investment in the industry, it is good to see companies raising money through funding rounds and investing in new facilities, as well as government support coming through to boost research in areas of urgent need.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery Today
MAY 26, 2023
BARCELONA/LONDON, 25.05.23: Seqera Labs, the leading provider of secure workflow orchestration software in the life sciences sector, has partnered with Genomics England, the government-owned company that launched the 100,000 Genomes Project in partnership with the NHS. The new collaboration between Seqera Labs and Genomics England will enable whole genome analysis to be carried out at a larger scale with greater efficiency, helping more patients benefit from genomic healthcare and equipping rese
Chemical Biology and Drug Design
MAY 25, 2023
PTP1B is a negative insulin signaling pathway regulator; hence, inhibiting PTP1B increases insulin sensitivity, glucose absorption, and energy expenditure. Abstract Diabetes mellitus (DM) is a serious global health concern affecting over 500 million people. To put it simply, it is one of the most dangerous metabolic illnesses. Insulin resistance is the root cause of 90% of all instances of diabetes, all of which are classified as Type 2 DM.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Hunter
MAY 22, 2023
We couldn’t include everything in Molecules of the Month, but here’s a round-up of up of 16 additional molecules of potential interest that we didn’t have space for in April, including a highly selective caspase inhibitor from a non-catalytic cysteine, a GPR40 AgoPAM from BMS with activity on GLP-1, a few examples of both on- and off-target toxicities, and several clinical candidates. 1.
Drug Discovery World
MAY 26, 2023
AnaMar has announced positive results from its Phase I study, and the completion of Phase II enabling pre-clinical studies, for AM1476’s initial orphan indication in systemic sclerosis (SSc) characterised by lung and skin fibrosis. AM1476, a highly selective small molecule, delivered as an orally administered tablet, was found to be safe and well-tolerated at all relevant doses in a trial of approximately 100 healthy subjects.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Chemical Biology and Drug Design
MAY 23, 2023
Lanosterol 14α-demethylase (CYP51) responsible for oxidative removal of 14α-methyl group of sterol precursors, lanosterol, and 24(28)-methylene-24,25-dihydrolanosterol in ergosterol biosynthesis; essential component of fungal life cycle and prominent target for antifungal drug development. This review addresses various azole- and non-azoles-based derivatives as potential antifungal agents that target fungal CYP51.
Drug Hunter
MAY 21, 2023
This article highlights six recent articles of interest in the field of targeted protein degradation including but not limited to potentially new ligases, recruiting motifs, and a discussion on the feasibility of CNS-penetrant degraders. 1. “Reinstating targeted protein degradation with DCAF1 PROTACs in CRBN PROTAC resistant settings” Novartis, Basel, CH + Cambridge, MA BioRxiv , April 14, 2023 This Novartis study identified a novel non-covalent ligand for the E3 ligase receptor DCAF1 for use in
Drug Discovery World
MAY 26, 2023
Danish start-up InProTher has raised €6 million seed funding from private investors, with participation from the European Innovation Council (EIC) Fund. The financing will enable InProTher to advance its lead drug candidate, IPT001, a first-in-class immunotherapy against solid tumours, into clinical development. Incubated at the BioInnovation Institute (BII) and seeded by the Novo Nordisk Foundation, InProTher was established to develop immunotherapies designed to overcome the limitations of can
Drug Patent Watch
MAY 22, 2023
Introducing DrugChatter.com: Empowering Access to Biopharmaceutical Drug Insights through AI Chat We are pleased to introduce DrugChatter.com, a groundbreaking platform that redefines the way professionals obtain concise, cited information on… The post DrugChatter.com: AI Chat for Biopharmaceutical Drug Insights appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Chemical Biology and Drug Design
MAY 21, 2023
Lericiresinol inhibited RA-induced inflammation by maintaining the delicate balance of pro-inflammatory and anti-inflammatory cytokines. It exhibits a strong anti-inflammatory effect against CFA rats via interfering with TGF-α and NF-κB. Abstract Rheumatoid arthritis (RA) is a severe inflammatory auto-immune disorder affecting millions of people across the globe.
Antidote
MAY 25, 2023
Lupus is a chronic, autoimmune disease that can be extremely difficult to identify and treat. Lupus can occur in anyone , and symptoms can range from mild to life threatening. Consequently, raising awareness and promoting early diagnosis is so important to identify and manage this condition.
Drug Discovery World
MAY 25, 2023
Pyxis Oncology has announced a definitive agreement by which it will acquire Apexigen in an all-stock transaction for an implied value of $0.64 per Apexigen share. For each share of Apexigen, Pyxis Oncology will issue 0.1725 shares of its common stock, par value $0.001 per share, for a total enterprise value of approximately $16 million. “This acquisition uniquely positions Pyxis Oncology at the forefront of antibody-drug conjugate (ADC) innovation by adding humanised antibody generation to our
Drug Channels
MAY 24, 2023
In The Top Pharmacy Benefit Managers of 2022: Market Share and Trends for the Biggest Companies , I shared Drug Channels Institute's analysis showing that three pharmacy benefit managers (PBMs)—the Caremark business of CVS Health, the Express Scripts business of Cigna, and the OptumRx business of UnitedHealth Group—accounted for about 80% of total equivalent prescription claims in 2022.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Chemical Biology and Drug Design
MAY 20, 2023
Compound 2h was identified as the most potent inhibitor of T3SS, which showed strong inhibitory effects on the secretion of the SPI-1 effector proteins in a dose-dependent manner. The compound 2h might affect the SPI-1 genes transcription via impacting the SicA / InvF regulatory pathway. Abstract A series of novel 5-amido-2-carboxypyrazine derivatives were designed, synthesized and evaluated for the inhibitory activities against the T3SS of Salmonella enterica serovar Typhimurium.
KIF1A
MAY 24, 2023
What do worms, a classroom full of students, and members of the KAND family community have in common? A lot more than you’d think! In this blog post, KIF1A.ORG Chief Science Officer Dr. Dominique Lessard describes a unique cross disciplinary experience with multiple scientific stakeholders in the rare disease space, all focused around our holistic understanding of KAND.
Drug Discovery World
MAY 25, 2023
Following the Scottish Research and Drug Development Forum meeting, DDW’s Diana Spencer provides a snapshot of drug discovery in Scotland. With over 150 pharma services/supply companies and 19 universities, Scotland is one of the most advanced life science sectors in the UK and the world. To demonstrate how Scotland is continuing to innovate and shape drug discovery, on April 27, 2023, ELRIG UK hosted the Scottish Research and Drug Development Forum at the Beatson Institute for Cancer Research i
Drug Channels
MAY 23, 2023
In 2022, the PBM market remained highly consolidated—although there were some intriguing share shifts among the largest players. Below, you’ll find Drug Channels Institute's latest estimates of pharmacy benefit manager (PBM) market share based on equivalent prescription claims. I also provide commentary on recent market developments and offer some helpful tips for interpreting the figures.
Drug Policy Alliance
MAY 24, 2023
Minnesota Becomes 2nd State to Officially Support Overdose Prevention Centers msutton Wed, 2023-05-24 17:54 Wed, 05/24/2023 - 17:54
Antidote
MAY 22, 2023
Participating in a clinical trial can be a worthwhile opportunity for any individual. Whether taking part as a healthy volunteer or enrolling in a study for a specific condition, being a medical research participant can provide the chance to be more involved in medical treatments, gain access to potential new therapies, and pave the way for medical breakthroughs to take place.
Drug Discovery World
MAY 25, 2023
The UK government will invest up to £39 ($48) million in antimicrobial resistance (AMR) research through the Global AMR Innovation Fund (GAMRIF). The funding includes up to £25 ($30.9) million awarded to support the early development of new antibiotics, vaccines, rapid diagnostics and other products to combat life-threatening drug-resistant infections.
KIF1A
MAY 20, 2023
#ScienceSaturday posts share exciting scientific developments and educational resources with the KAND community. Each week, Dr. Dominique Lessard and Dr. Dylan Verden of KIF1A.ORG summarize newly published KIF1A-related research and highlight progress in rare disease research and therapeutic development. KIF1A-Related Research Optogenetic control of kinesins and dynein reveals their specific roles in vesicular transport KIF1A is only one of over 40 kinesin motor proteins in mammals, so why do KI
Science Daily: Pharmacology News
MAY 25, 2023
There is a massive, mineral-rich region in the Pacific Ocean -- about twice the size of India -- called the Clarion-Clipperton Zone (CCZ), which has already been divided up and assigned to companies for future deep-sea mining. To better understand what may be at risk once companies start mining, a team of biologists has built the first 'CCZ checklist' by compiling all the species records from previous research expeditions to the region.
biobide
MAY 26, 2023
Cancer is a devastating and complex disease, generated by an alteration in the cells, caused by genetic and epigenetic alterations that produce a loss of cell control mechanisms. This transforms the affected cells into uncontrolled entities able to grow limitlessly and disseminate through the organs, damaging them, and causing in the end the irremediable demise of the patient if it is not treated.
Drug Discovery World
MAY 25, 2023
Several new products for the life sciences sector have been launched over the last month, from miniature semiconductor chip (MSC) technology to a new inhalation testing service. DDW provides an update. GenScript Biotech Corporation: GenTitan Gene Fragments Synthesis service Powered by GenScript’s miniature semiconductor chip (MSC) technology, GenTitan gives scientists access to high-throughput, synthetic DNA, to accelerate progress in the fields of synthetic biology, protein and antibody enginee
Drug Policy Alliance
MAY 25, 2023
Washington, D.C. – Today, the U.S. House of Representatives passed the Halt All Lethal Trafficking of Fentanyl (HALT) Act (H.R. 467) in a 289-133 vote. This legislation would ramp up mandatory minimum sentencing for fentanyl analogues. It would also permanently schedule all fentanyl-related substances as Schedule I without first testing them for benefits or harm.
Science Daily: Pharmacology News
MAY 24, 2023
A team of engineers has recently shown that nearly any material can be turned into a device that continuously harvests electricity from humidity in the air. Researchers describe the 'generic Air-gen effect'-- nearly any material can be engineered with nanopores to harvest, cost effective, scalable, interruption-free electricity. The secret lies in being able to pepper the material with nanopores less than 100 nanometers in diameter.
The Pharma Data
MAY 26, 2023
Bolivia conducts a simulation exercise to strengthen the National Deployment and Vaccination Plan for influenza and other respiratory viruses As part of a series of twelve workshops to identify lessons learned from COVID-19 and to develop a pandemic preparedness plan for influenza and other respiratory viruses (ORVs), a simulation exercise in Bolivia was carried out using a board game to strengthen the deployment of pandemic products.
Drug Discovery World
MAY 24, 2023
Touchlight, a company providing DNA services and manufacturing enzymes, has completed the redevelopment and expansion of its UK manufacturing facility in London, UK. The expanded facility’s manufacturing capacity has tripled and is now capable of producing more than 8kg a year. This exceeds the current, but growing, global supply of plasmid DNA for genetic medicine, and dramatically increases Touchlight’s capacity to meet growing demand for DNA from biopharmaceutical companies.
addgene Blog
MAY 23, 2023
You may be familiar with immunofluorescence (IF, often referred to as immunocytochemistry (ICC) when the sample is cultured cells or immunohistochemistry (IHC) with tissues), where an antibody binds a target protein in your sample, then a fluorescently labeled secondary antibody binds that first antibody, then you use a microscope to see where the target protein is (localization) and how much there is (quantification).
Science Daily: Pharmacology News
MAY 25, 2023
New animal research is helping explain why at least five people have become HIV-free after receiving a stem cell transplant, and may bring scientists closer to developing what they hope will be a widespread cure for the virus that causes AIDS. A new study describes how two nonhuman primates were cured of the monkey form of HIV after receiving a stem cell transplant.
The Pharma Data
MAY 26, 2023
WHO urges governments to stop subsidizing life-threatening tobacco crops On World No Tobacco Day , WHO urges governments to stop subsidizing tobacco farming and support more sustainable crops that could feed millions. “Tobacco is responsible for 8 million deaths a year, yet governments across the world spend millions supporting tobacco farms,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.
Drug Discovery World
MAY 24, 2023
Altering the chemical properties of an anti-nausea drug enables it to enter an interior compartment of the cell and provide long-lasting pain relief, according to a new study led by researchers at NYU College of Dentistry’s Pain Research Center. The study, published in the Proceedings of the National Academy of Sciences (PNAS), illustrates how pain signalling occurs inside cells rather than at the surface, highlighting the need for drugs that can reach receptors within cells.
Crucial Data Solutions
MAY 26, 2023
If you are working in clinical trials in any capacity, you know the way we do studies has changed dramatically. The post The Power of One Unified and Comprehensive Data Platform for Clinical Trials appeared first on Crucial Data Solutions.
Expert insights. Personalized for you.
144 
Let's personalize your content